Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MPN Advances Day 2019 | Cardiotoxicity in hematology oncology: MPNs

Arjun Ghosh • 15 Nov 2019
MPN Advances Day 2019
Myeloproliferative Neoplasms

Arjun Ghosh, MBBS, MRCP(UK), MRCP(Cardiology), PhD, FHEA, FACC, Barts Health NHS Trust & University College London Hospitals NHS Foundation Trust, London, UK, gives an overview of the most common cardiotoxicities in hematology oncology, focusing on MPNs. This interview took place at the Myeloproliferative Neoplasms Advances Day 2019 in London, UK.

More from Arjun Ghosh

1:07
Cardiology updates for hematologists
Arjun Ghosh • 15 Nov 2019

Related Videos

2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals